Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, Yesterday

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 2 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
5 days ago
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.

Ginkgo biloba extract improves cognition and overall condition after ischaemic stroke

Christina Lau
23 Nov 2018
Dr Yanxin Zhao speaking at VasCog 2018

Use of a ginkgo biloba extract on top of standard preventive treatment is shown to improve cognitive function and overall condition after acute ischaemic stroke. 

In a multicentre pilot study, patients aged ≥50 years (n=201) who had an ischaemic stroke 7–14 days before baseline were randomized to receive standard treatment for prevention of stroke recurrence with or without EGb 761, a ginkgo biloba extract taken three times daily, for 24 weeks.

“Results showed significant improvements in cognitive function, mainly in memory, language, orientation and processing speed, in the EGb 761 vs standard treatment group, as assessed by Montreal Cognitive Assessment [MoCA] and Hopkins Verbal Learning Test [HVLT],” reported investigator Dr Yanxin Zhao of Fudan University, Shanghai, China, at VasCog 2018.

“Eighty percent of patients in the EGb 761 group had very much or much improved overall condition, compared with 20 percent of patients in the standard treatment group [p<0.05]. Neuropsychiatric symptoms and stroke-related symptoms were very mild at baseline, and improved slightly and to similar degrees in both groups,” he continued. “EGb 761 was safe and well tolerated in the study.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Psychiatry - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, Yesterday

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 2 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
5 days ago
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.